1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Metabolic Dysfunction-Associated Steatohepatitis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2019-2024) and Forecast (2025-2035)
4.4 Market Overview (2019-2024) and Forecast (2025-2035)
4.5 Competitive Intelligence
5 Metabolic Dysfunction-Associated Steatohepatitis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Metabolic Dysfunction-Associated Steatohepatitis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2019-2024)
7.2.2 Epidemiology Forecast (2025-2035)
7.2.3 Epidemiology by Age (2019-2035)
7.2.4 Epidemiology by Gender (2019-2035)
7.2.5 Diagnosed Cases (2019-2035)
7.2.6 Patient Pool/Treated Cases (2019-2035)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2019-2024)
7.3.2 Epidemiology Forecast (2025-2035)
7.3.3 Epidemiology by Age (2019-2035)
7.3.4 Epidemiology by Gender (2019-2035)
7.3.5 Diagnosed Cases (2019-2035)
7.3.6 Patient Pool/Treated Cases (2019-2035)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2019-2024)
7.4.2 Epidemiology Forecast (2025-2035)
7.4.3 Epidemiology by Age (2019-2035)
7.4.4 Epidemiology by Gender (2019-2035)
7.4.5 Diagnosed Cases (2019-2035)
7.4.6 Patient Pool/Treated Cases (2019-2035)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2019-2024)
7.5.2 Epidemiology Forecast (2025-2035)
7.5.3 Epidemiology by Age (2019-2035)
7.2.4 Epidemiology by Gender (2019-2035)
7.5.5 Diagnosed Cases (2019-2035)
7.5.6 Patient Pool/Treated Cases (2019-2035)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2019-2024)
7.6.2 Epidemiology Forecast (2025-2035)
7.6.3 Epidemiology by Age (2019-2035)
7.6.4 Epidemiology by Gender (2019-2035)
7.6.5 Diagnosed Cases (2019-2035)
7.6.6 Patient Pool/Treated Cases (2019-2035)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2019-2024)
7.7.2 Epidemiology Forecast (2025-2035)
7.7.3 Epidemiology by Age (2019-2035)
7.7.4 Epidemiology by Gender (2019-2035)
7.7.5 Diagnosed Cases (2019-2035)
7.7.6 Patient Pool/Treated Cases (2019-2035)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2019-2024)
7.8.2 Epidemiology Forecast (2025-2035)
7.8.3 Epidemiology by Age (2019-2035)
7.8.4 Epidemiology by Gender (2019-2035)
7.8.5 Diagnosed Cases (2019-2035)
7.8.6 Patient Pool/Treated Cases (2019-2035)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2019-2024)
7.9.2 Epidemiology Forecast (2025-2035)
7.9.3 Epidemiology by Age (2019-2035)
7.9.4 Epidemiology by Gender (2019-2035)
7.9.5 Diagnosed Cases (2019-2035)
7.9.6 Patient Pool/Treated Cases (2019-2035)
8 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Unmet Needs
10 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Key Endpoints of Treatment
11 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Marketed Products
11.1 List of Metabolic Dysfunction-Associated Steatohepatitis Treatment - Marketed Drugs Across the Top 7 Markets
11.1.1 Rezdiffra (Resmetirom) - Madrigal Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Clinical Trial Results
11.1.1.4 Safety and Efficacy
11.1.1.5 Regulatory Status
Complete list to be provided in the final report.
12 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Pipeline Products
12.1 List of Metabolic Dysfunction-Associated Steatohepatitis Treatment Pipeline Drugs Across the Top 7 Markets
12.1.1 Pegozafermin – 89bio
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Efruxifermin – Akero Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Miricorilant – Corcept Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ALG-055009 – Aligos Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 ALN-HSD – Regeneron Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Complete list to be provided in the final report.
13 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Attribute Analysis of Key Marketed and Pipeline Drugs
14 Metabolic Dysfunction-Associated Steatohepatitis Treatment – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Metabolic Dysfunction-Associated Steatohepatitis Treatment Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
15.2.1.1 Market Size (2019-2024)
15.2.1.2 Market Forecast (2025-2035)
15.2.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
15.2.2.1 Market Size by Therapies (2019-2024)
15.2.2.2 Market Forecast by Therapies (2024-2035)
15.3 Market Scenario - United States
15.3.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
15.3.1.1 Market Size (2019-2024)
15.3.1.2 Market Forecast (2025-2035)
15.3.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
15.3.2.1 Market Size by Therapies (2019-2024)
15.3.2.2 Market Forecast by Therapies (2025-2035)
15.3.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
15.4.1.1 Market Size (2019-2024)
15.4.1.2 Market Forecast (2025-2035)
15.4.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
15.4.2.1 Market Size by Therapies (2019-2024)
15.4.2.2 Market Forecast by Therapies (2025-2035)
15.4.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
15.5.1.1 Market Size (2019-2024)
15.5.1.2 Market Forecast (2025-2035)
15.5.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
15.5.2.1 Market Size by Therapies (2019-2024)
15.5.2.2 Market Forecast by Therapies (2025-2035)
15.5.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
15.6 Market Scenario – United Kingdom
15.6.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
15.6.1.1 Market Size (2019-2024)
15.6.1.2 Market Forecast (2025-2035)
15.6.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
15.6.2.1 Market Size by Therapies (2019-2024)
15.6.2.2 Market Forecast by Therapies (2025-2035)
15.6.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
15.7 Market Scenario – Italy
15.7.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
15.7.1.1 Market Size (2019-2024)
15.7.1.2 Market Forecast (2025-2035)
15.7.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
15.7.2.1 Market Size by Therapies (2019-2024)
15.7.2.2 Market Forecast by Therapies (2025-2035)
15.7.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
15.8.1.1 Market Size (2019-2024)
15.8.1.2 Market Forecast (2025-2035)
15.8.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
15.8.2.1 Market Size by Therapies (2019-2024)
15.8.2.2 Market Forecast by Therapies (2025-2035)
15.8.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
15.9.1.1 Market Size (2019-2024)
15.9.1.2 Market Forecast (2025-2035)
15.9.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
15.9.2.1 Market Size by Therapies (2019-2024)
15.9.2.2 Market Forecast by Therapies (2025-2035)
15.9.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Access and Reimbursement Overview
16 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Recent Events and Inputs From Key Opinion Leaders
17 Metabolic Dysfunction-Associated Steatohepatitis Treatment Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Metabolic Dysfunction-Associated Steatohepatitis Treatment – Strategic Recommendation
19 Appendix